Healthcare >> CEO Interviews >> September 17, 2014

Interview with the President and CEO and the Chief Scientific Officer: VolitionRX Limited (VNRX)

Micallef, Jake
Dr. Jake Micallef, Ph.D., is the Chief Scientific Officer of VolitionRX Limited. He is an experienced scientific executive with expertise in research and development, and in the management of early-stage biotechnical companies, including the manufacture of biotechnology products and the establishment of manufacturing operations. Dr. Micallef gained this experience while working for the World Health Organization, or WHO, over a 10-year period from 1985. While working for the WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990, he commenced development of a new diagnostic technology platform for WHO, which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture — previously outsourced to Abbott Diagnostics Inc. — and worldwide distribution of these products for WHO. In 1990, he started a not-for-profit WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide. In 1999, Dr. Micallef studied for an MBA and went on to co-found Gene Expression Technologies in 2001, where he successfully lead the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer Pharmaceuticals. From 2004 to 2007, he taught science and enterprise to science research workers from four universities at Cass Business School before joining Cronos Therapeutics in 2004. In 2006, Cronos was listed in the U.K. on AIM becoming ValiRx. Dr. Micallef continued to work as Technical Officer for ValiRx, where he in-licensed the HyperGenomics and Nucleosomics technologies, and co-founded ValiBIO SA, which is now Belgian Volition SA, a subsidiary of Singapore Volition. Dr. Micallef was educated at King’s College London, earning a B.S. in biology and chemistry, and a Ph.D. in physical chemistry; St Thomas’ Hospital Medical School, London, earning an M.S. in chemical pathology; and Imperial College Management School, earning an MBA. Profile
Reynolds, Cameron
Cameron Reynolds is the President and Chief Executive Officer of VolitionRX Limited. He is an experienced entrepreneurial executive with expertise in mining and biotechnology companies. He has strong experience in the management, structuring and strategic planning of startup companies and has held positions including CEO, CFO and Non-Executive Director of public and private enterprises. Mr. Reynolds has returned to his life sciences and biotechnology roots, where, in 1996, he began working for Integrated Coffee Technologies — a genetically modified coffee company — in a junior management position, where he was responsible for business-plan creation, office management, recruitment and business development. After working for Integrated Coffee Technologies, Mr. Reynolds served as the commercialization director for ProBio, Inc., a company that commercialized intellectual property in the animal biotechnology fields, including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds held that role from 1998 until 2001, and his main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all shareholder issues, including the merger, and its legal and contractual documentation; head office management; budgetary control; team building; and recruitment. From 2004 until 2011, Mr. Reynolds founded and served as Managing Director and Director of Mining House Limited, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on AIM, TSX and U.S. OTC. From 2005 until present, Mr. Reynolds has held a number of board directorships, including Atlantic Mining PLC; Carbon Mining PLC, and Magellan Copper and Gold — Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp on AIM, CDC.L after a vend; KAL Energy Inc. (KALG); Iofina Natural Gas PLC (IOF.L); Canyon Copper Corp. (CNC.V, CNYCF); and Hunter Bay Resources (HBY.V). Mr. Reynolds was educated at the University of Western Australia, earning a Bachelor of Commerce and an MBA. Profile
TWST: Can you provide an overview of the company and discuss your technology?

Mr. Reynolds: We are a cancer diagnostics company with a blood-based test currently that is very